MMS

MMS is an innovative, data-focused CRO that supports the pharmaceutical, biotech, and medical device industries with a proven, scientific approach.

MMS Holdings (MMS) is an innovative, data-focused CRO that supports the pharmaceutical, biotech, and medical device industries with a proven, scientific approach to complex trial data and regulatory submission challenges. Strong industry experience, technology-enabled services, and a data-driven approach to drug development make MMS a valuable CRO partner, creating compelling submissions that meet rigorous regulatory standards. With a global footprint across four continents, MMS maintains a 97 percent customer satisfaction rating, and the company has been recognized as a leading CRO in Global Health & Pharma’s international awards programs for three consecutive years.

01/28/2026

Read one of our latest case studies to see how sponsors partnered with MMS to develop a robust briefing book that supported effective interactions with health authorities and strengthened strategic defenses through clear evidence and organized presentation!

Key takeaways from this project include:
📌 Better alignment with regulatory expectations through structured content and thorough evidence mapping
📌 Improved efficiency and quality by leveraging expertise in regulatory strategy and document development
📌 Stronger defense preparedness during sponsor-regulator engagements supported by thoughtful presentation of data and rationale

Get the full details here: https://hubs.li/Q03_gDm80

01/27/2026

We know that many Chief Medical Officer’s could benefit from a playbook that details the following:

✅ Why investors value trial design as much as the science itself
✅ How biostatistics can de-risk your program and protect capital
✅ The hidden power of the CMO + statistician partnership
✅ Practical strategies and a readiness checklist to strengthen your pitch
✅ How simulation transforms trial planning into a fundraising advantage

We created just that! Download your complimentary copy now: https://hubs.li/Q040rspv0

01/22/2026

Have you wondered what “AI singularity” means for the future of how we analyze data, design models, and support decisions in clinical development?

In one of our latest Perspectives article, we explore how emerging AI capabilities could influence the future of biometrics, from where human expertise remains essential to how sponsors and CROs can prepare for intelligent systems that operate alongside statisticians and data scientists.

If you are interested in the intersection of AI, data integrity, and clinical evidence generation, this piece offers a thoughtful look: https://hubs.li/Q03_4LC70

01/21/2026

Clinical trial design is becoming more complex, and Sponsors need clearer insight earlier to make confident decisions! To that end, we would like to invite you to join our upcoming webinar next week to explore how data-driven design, in-stream analytics, and AI are reshaping trial feasibility, ex*****on, and outcomes.

In this session, Irving Dark, Chris Schoonmaker, and Stephine Keeton will discuss:

📊 Key trends driving trial design complexity
📊 How modelling and simulation support smarter design and operational decisions
📊 Real-world examples of improved efficiency through data-driven approaches
📊 In-stream analytics for earlier risk detection and mitigation
📊 The expanding role of AI across biometrics, operations, and documentation

Register to attend: https://hubs.li/Q03_5v9w0

01/20/2026

How do you identify the right clinical trial design the first time? Using KerusCloud®, MMS helps Sponsors simulate multiple pathways before a single patient is enrolled. This saves time, generates more evidence, and dramatically increases the probability of success.

In fact, KerusCloud® has been shown to increase the probability of success of a single study by 41%, all while staying within the same budget.

Explore it now: https://hubs.li/Q03_rQ5q0

01/19/2026

We’re growing and hiring across multiple teams at MMS, and right now we are looking for our next remote Project Manager in the UK! Could that be you or someone you know?

This role drives complex cross-functional programs, strengthens client relationships, and supports clinical research ex*****on with strong scientific understanding and project leadership! Appy now, here: https://hubs.li/Q03_4t0F0

We’re also looking for talented professionals, like Document Reviewers, Medical Writers (Senior, Principal, and Project-Based roles), Sales and Business Development roles, and additional positions across biometrics, regulatory operations, and quality assurance.

Share this post to support those in your network looking for their next role!

01/16/2026

Do you believe that timely access to high-quality data is essential for confident decision making in clinical development? So do we.

That’s why we created Datacise!

WATCH this short video to learn about this innovative cloud-based platform designed to aggregate, mine, and visualize clinical and real-world data to deliver real-time insights for Sponsors. Built with security and scalability at its core, Datacise enables teams to move with a sense of urgency and leadership in a whole new way.

See how Datacise is shaping data-driven leadership here: https://hubs.li/Q03_44NQ0

01/15/2026

MMS is on-site this week at the JPMorgan Healthcare Conference in San Francisco, engaging in timely discussions across the life sciences ecosystem!

Conversations this week are spanning investors, sponsors, and innovators, all focused on advancing clinical development through stronger evidence generation, thoughtful use of technology, and clear regulatory strategy! MMS is contributing its perspectives of what’s possible for a go-to-market strategy when a trial is designed better, innovative regulatory approaches are engaged, and the right people, processes, and technology are in place.

If you are attending and would value a discussion on trial design, biometrics, regulatory pathways, or technology-enabled development, we welcome the opportunity to connect while on site!

Learn about the event here: https://hubs.li/Q03-xtGP0

Request a meeting here: https://hubs.li/Q03-xtww0

01/14/2026

Writing 800 clinical narratives under tight timelines may seem impossible, but not when combined with expert storytelling, structured workflows, and scalable ex*****on! In one of our latest public case studies, we detail how MMS achieved the following:

📌 Scalable narrative production through disciplined planning and specialized writing teams
📌 Quality you can trust with structured review and regulatory alignment
📌 Enhanced sponsor confidence in submission delivery through clear, consistent narrative outputs

If your team is navigating large-scale narrative demands or tight regulatory timelines, read the full case study here: https://hubs.li/Q03-lSMX0

01/13/2026

We’re excited that MMS will be sponsoring and speaking at the RAPS San Francisco Bay Area in-person event on Innovative Trial Designs and Regulatory Strategies to Advance Clinical Development in February!

This discussion-driven session will feature Steve Heitner, VP Clinical Research of Cytokinetics, Aiden Flynn, SVP Statistical Consulting at MMS, and Ben Kaspar, VP Regulatory Strategy at MMS, as well as moderation from our own April Nguyen, Associate Director Regulatory Strategy at MMS and RAPS SF Chapter volunteer.

As clinical research becomes more complex, sponsors and regulatory professionals need new approaches for trial design, evidence strategy, and regulatory alignment. This event brings the community together to explore practical solutions that strengthen how we bring therapies forward!

Register to attend now: https://hubs.li/Q03-xBSM0

01/12/2026

Listen to this clip! Medical writing is entering a phase where multiple AI tools may sit inside the same project workflow, but how should writers operate in that environment?

Hear from our experts on how we are thinking about the role of human expertise alongside expanding AI capabilities. And, after you watch, share your thoughts in the comments!

How do you see medical writers adapting as AI tools become more common across projects?

01/09/2026

The word “Expedited” in drug development often gets mistaken for speed alone! In reality, it means designing programs with clarity, alignment, and strong evidence from the start. Our latest article breaks down what expedited pathways really require and how sponsors can plan accordingly.

Key takeaways include:
🔎 Focused evidence generation aligned with regulatory expectations
🔎 Early and intentional engagement with health authorities
🔎 Efficient development driven by strategy and data quality

Read the full Perspectives article here: https://hubs.li/Q03-852D0

Address

6880 Commerce Boulevard
Canton, MI
48187

Telephone

+17342450310

Website

http://www.mmsholdings.com/

Alerts

Be the first to know and let us send you an email when MMS posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to MMS:

Shortcuts

Want your practice to be the top-listed Clinic in Canton?

Our Story

MMS is an award-winning, data-focused CRO that supports the pharmaceutical and biotech industries with a proven, scientific approach to complex trial data and regulatory submission challenges. Strong industry experience and a data-driven approach to drug development make MMS a valuable CRO partner, creating compelling submissions that meet rigorous regulatory standards. With a global footprint across four continents, MMS maintains a 97 percent customer satisfaction rating and was named as the Best Global Biotech CRO in the 2018 International Life Sciences Awards.